A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years

Neisseria Meningitides Meningitis Clinical Trial

Official title:

A Phase IV Randomized, Observer-blind, Controlled Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine as Compared to Sanofi Pasteur Menactra® Vaccine in Healthy Subjects Aged 2-10 Years

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04450498
• Other study ID #: MPV ACYW-004
• Status: Completed
• Phase: Phase 4
• Start date: December 23, 2020
• Est. completion date: July 30, 2021

Study information

• Verified date: July 2023
• Source: Walvax Biotechnology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase IV, single-center, observer-blind, randomized, controlled vaccine trial in 2 to 10 years old healthy subjects. Each participant will receive a single intramuscular injection of one of the two vaccines either MPV ACYW® vaccine or Menactra ® vaccine according to the vaccine group assignment and will be followed up for one month for immunogenicity evaluation and for 6 months for safety evaluation.

Statistical Hypothesis:

H0: Seroconversion rate of test group is inferior to that of control group HA: Seroconversion rate of test group is non-inferior to that of control group Sample size calculation: the sample size was calculated based on non-inferiority test with alpha level of 0.025 and 80% power, assuming seroconversion rate in control group was 95% with non-inferiority margin at 10%. The sample size required for the study is 124 per arm. After adjusting for 5% drop-out, the final sample size required is 130 per arm.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 260
• Est. completion date: July 30, 2021
• Est. primary completion date: July 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Years to 10 Years

Eligibility

Inclusion Criteria:

• Age 2 to 10 years of age (both included)

• Written informed consent obtained from the mother, father, or guardian of the child.

• Free of obvious health problems and be fully vaccinated according local EPI schedule as established by medical history including physical examination and clinical judgment of the investigator.

• Mother, father, or guardian capable and willing to bring their child or to receive home visits for their child for all follow-up visits.

• Residence in the study area during the study period.

Exclusion Criteria:

• Vaccination against group A,C,Y,W Neisseria meningitidis in the previous 3 months

• History of allergic disease or known hypersensitivity to any component of the two study vaccines.

• History of serious adverse reactions following administration of vaccines included in the local program of immunization.

• Administration of any other vaccine within 30 days prior to administration of study vaccines or planned vaccination during the first four weeks after the study vaccination.

• Use of any investigational or nonregistered product within 60 days prior to the administration of study vaccines.

• Administration of immunoglobulins and/or any blood products or planned administration during the study participation period.

• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying agents since birth (including systemic or inhaled corticosteroids, this means prednisone, or equivalent, =0.5 mg/kg/day; topical steroids are allowed).

• A family history of congenital or hereditary immunodeficiency.

• History of meningitis or seizures, or any neurological disorder, convulsions, or active tuberculosis.

• Major congenital defects or serious chronic illness, including malnutrition (i.e., weight less than or equal to 3 standard deviations below the mean for 2-5 years old) and immunodeficiency disorder (as per investigator's judgment)

• Acute disease at the time of enrollment (acute disease being defined as the presence of a moderate or severe illness with or without fever) resulting in a temporary exclusion.

• Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by medical history, physical examination, or laboratory tests, which in the opinion of the investigator might interfere with the well-being of the subject study objectives.

• Any condition or criterion that in the opinion of the investigator might compromise the well-being of the subject or the compliance with study procedures or interfere with the outcome of the study

Related Conditions & MeSH terms

• Meningitis
• Meningitis, Meningococcal
• Neisseria Meningitides Meningitis

Intervention

Biological:
• Yuxi Walvax MPV ACYW® vaccine
Walvax MPV ACYW vaccine is a sterile formulation of polysaccharide A,C,Y,W-135. One dose of 0.5 mL contains 50 µg of each A,C,Y,W-135 purified polysaccharide. The vaccine is presented in two vials: one containing the lyophilized cake of A,C,Y,W purified polysaccharides and the other the sterile water for injection as diluent. After reconstitution the one dose of 0.5 mL is ready for subcutaneous injection. The antigen content is similar to other internationally marketed polysaccharide vaccines that have been in use for decades as Menomune® Sanofi and Mencevax® Pfizer , all containing 50 µg of each A,C,Y,W purified polysaccharide that as one dose schedule are recommended for use in subjects > 2 years of age and have shown to be safe and immunogenic.
• Sanofi Pasteur Menactra® vaccine
The vaccine presentation is a full liquid formulation in a single dose of 0.5 mL with the following composition: Meningococcal group A polysaccharide 4 µg; Meningococcal group C polysaccharide 4 µg; Meningococcal group Y polysaccharide 4 µg; Meningococcal group W polysaccharide 4 µg; Diphtheria toxoid protein total 48 µg; Sodium phosphate 0.7 mg; Sodium chloride 4.35 mg.

Locations

Country	Name	City	State
Mali	Centre pour le Développement des Vaccins du Mali	Bamako

Sponsors (1)

Lead Sponsor	Collaborator
Walvax Biotechnology Co., Ltd.

Country where clinical trial is conducted

Mali, 

References & Publications (1)

Sow SO, Tapia MD, Haidara FC, Diallo F, Traore Y, Traore A, Kodio M, Borrow R, Townsend-Payne K, Yuan L, Yang S, Shi L, Chen J, Fang G, Lin J, Hu R, Viviani S, Huang Z. Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV AC — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antibody response at Day 30 post-vaccination	Percentage of subjects with rSBA (Serum Bactericidal Activity using baby rabbit complement) titer =1:128 to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups 30 days after immunization	Day 30 post-vaccination
Secondary	Percentages of subjects with post-immunization local and systemic reactions within 7 days following vaccination in both vaccine groups		Day 7 post-vaccination
Secondary	Percentages of subjects with reported Adverse Events within 30 days following vaccination in both vaccine groups		Day 30 post-vaccination
Secondary	Percentages of subjects with reported SAEs within 6 months following vaccination in both vaccine groups		Day 30 to Day 180 post-vaccination (end of study visit)
Secondary	rSBA Geometric mean antibody titers to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups		Day 30 post-vaccination
Secondary	Percentage of subjects with rSBA titer =1:8 to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups 30 days after immunization		Day 30 post-vaccination
Secondary	Seroconversion rates as defined by proportion of subjects with = 4-fold increase 30 days after immunization with respect to baseline of rSBA antibodies to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups 30 days after immunization		Day 30 post-vaccination
Secondary	Seroconversion rates as defined by proportion of subjects with = 2-fold increase 30 days after immunization with respect to baseline of rSBA antibodies to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups		Day 30 post-vaccination